Bausch + Lomb Corp (NYSE:BLCO) is reportedly considering a sale as it navigates separation issues from its parent company, ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Bausch+Lomb, valued at over $10 billion ... with nearly 60% coming from contact lenses and eye drugs. The potential sale is part of efforts to address concerns from creditors like Apollo Global ...

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Consumer medical giant Bausch + Lomb may be preparing to sell off its eye care business, which would include contact lens ...

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...

Bausch + Lomb is working with advisers from Goldman Sachs to test interest from possible buyers, the Financial Times reported ...